Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $5.4 million.

  • Mirum Pharmaceuticals' Other Non-Current Assets rose 84.35% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year increase of 84.35%. This contributed to the annual value of $5.4 million for FY2024, which is 29.22% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Other Non-Current Assets of $5.4 million as of FY2024, which was up 29.22% from $4.2 million recorded in FY2023.
  • Mirum Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $5.4 million during FY2024, with a 5-year trough of $1.3 million in FY2020.
  • Its 3-year average for Other Non-Current Assets is $3.6 million, with a median of $4.2 million in 2023.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Other Non-Current Assets declined by 22.62% in 2022 and then skyrocketed by 201.37% in 2023.
  • Yearly analysis of 5 years shows Mirum Pharmaceuticals' Other Non-Current Assets stood at $1.3 million in 2020, then surged by 40.41% to $1.8 million in 2021, then dropped by 22.62% to $1.4 million in 2022, then soared by 201.37% to $4.2 million in 2023, then climbed by 29.22% to $5.4 million in 2024.